Protagonist Therapeutics (NASDAQ:PTGX) Director Bryan Giraudo Sells 6,000 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director Bryan Giraudo sold 6,000 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $100.00, for a total value of $600,000.00. Following the transaction, the director owned 31,825 shares in the company, valued at $3,182,500. This trade represents a 15.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Bryan Giraudo also recently made the following trade(s):

• On Friday, May 8th, Bryan Giraudo sold 5,130 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $100.00, for a total value of $513,000.00.
• On Thursday, May 7th, Bryan Giraudo sold 12,000 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $100.07, for a total transaction of $1,200,840.00.
• On Thursday, May 7th, Bryan Giraudo sold 36,000 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $100.14, for a total value of $3,605,040.00.

Protagonist Therapeutics Stock Performance

PTGX stock traded up $4.14 on Monday, reaching $103.50. The company’s stock had a trading volume of 572,030 shares, compared to its average volume of 669,567. The firm has a market cap of $6.66 billion, a PE ratio of -57.18 and a beta of 1.89. The business has a fifty day simple moving average of $99.95 and a two-hundred day simple moving average of $89.78. Protagonist Therapeutics, Inc. has a 12-month low of $43.20 and a 12-month high of $107.84.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.55. The firm had revenue of $56.37 million during the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. As a group, research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on PTGX shares. Citigroup reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. TD Cowen lifted their target price on Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Wedbush boosted their price target on Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Barclays upped their price target on Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a report on Thursday, March 19th. Finally, Citizens Jmp increased their price objective on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 6th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $113.69.

Hedge Funds Weigh In On Protagonist Therapeutics

Several large investors have recently modified their holdings of PTGX. PNC Financial Services Group Inc. boosted its stake in Protagonist Therapeutics by 35.1% during the first quarter. PNC Financial Services Group Inc. now owns 3,998 shares of the company’s stock worth $421,000 after buying an additional 1,039 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Protagonist Therapeutics by 22.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 508,103 shares of the company’s stock worth $53,542,000 after acquiring an additional 93,688 shares during the last quarter. AlphaCentric Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 9,040 shares of the company’s stock worth $953,000 after purchasing an additional 491 shares during the period. SEB Asset Management AB bought a new stake in shares of Protagonist Therapeutics during the 1st quarter worth approximately $24,497,000. Finally, Swiss National Bank boosted its holdings in Protagonist Therapeutics by 0.7% during the 1st quarter. Swiss National Bank now owns 98,900 shares of the company’s stock valued at $10,424,000 after acquiring an additional 700 shares during the period. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.